Latest News

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration

WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announces that the NDA for KPI-121 0.25% has been accepted for review by the U.S. FDA.

Source link

Related posts

African-American mothers rate boys higher for ADHD


'Report card' on American diet: Adults consuming more low-quality carbs and fat than recommended


Laparoscopic excision of deep rectovaginal endometriosis in BSGE endometriosis centres: a multicentre prospective cohort study


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World